Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CASP9 | P55211 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488980 | 1.00 | CTSL (0.59) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL15289789 | 0.90 | CTSL (0.59) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL15289840 | 0.90 | CTSL (0.59) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL2228720 | 0.88 | CA2 (0.63) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL4075762 | 0.86 | CTSS (0.65) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL5662889 | 0.85 | CA2 (0.61) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL5547819 | 0.85 | CA2 (0.61) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL5547822 | 0.85 | CA2 (0.61) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL5547827 | 0.85 | CA2 (0.61) | CTSLCTSSCA2CA5ACTSB | |
| SCHEMBL14401772 | 0.85 | CTSD (0.71) | CTSLCTSSCA2CA5ACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9814715-B2 | Liver X receptor modulators | VITAE PHARAMCEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9707232-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170136017-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170007603-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-9416135-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9388190-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | VITAE PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20150336963-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-11-26 | — | — | US | disclosed |
| US-20150250787-A1 | COMPOUNDS FOR USE IN TREATING SKIN CANCERS | VITAE PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150246924-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-09-03 | — | — | US | disclosed |
| US-9073931-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9006245-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006244-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150080406-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-03-19 | — | — | US | disclosed |
| US-20150065515-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150051214-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20150336963-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | CTSL 714/4885CTSS 264/4885CA2 877/4885 |
| US-20150065515-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20150051214-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | RET, RARS2, RARS1 | CTSL 4149/4885CTSS 1476/4885CA2 3312/4885 |
| US-20150246924-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20170136017-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20150250787-A1 | COMPOUNDS FOR USE IN TREATING SKIN CANCERS | TP53, KRT18, VHL | CTSL 2665/4885CTSS 1606/4885CA2 1470/4885 |
| US-20150080406-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | CTSL 714/4885CTSS 264/4885CA2 877/4885 |
| US-20170007603-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | CTSL 4166/4885CTSS 2794/4885CA2 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.